NADPH oxidase

Current Opinion in Immunology

Volumn 16, Issue 1, 2004, Pages 42-47

  Babior, Bernard M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; COTRIMOXAZOLE; PROTEIN; PROTEIN P22; PROTEIN P40; PROTEIN P47; PROTEIN P67; PROTEIN P91; PROTEIN SH3; RECOMBINANT GAMMA INTERFERON; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

CATALYST; CYTOSOL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; ENZYMOLOGY; GENETIC ANALYSIS; GRANULOMATOSIS; HUMAN; IMMUNE DEFICIENCY; PATHOGENESIS; PROPHYLAXIS; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; TREATMENT INDICATION; X RAY CRYSTALLOGRAPHY;

EID: 1042278903     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2003.12.001     Document Type: Review

References (65)

1. Ago T., Nunoi H., Ito T., Sumimoto H. Mechanism for phosphorylation- induced activation of the phagocyte NADPH oxidase protein p47(phox). Triple replacement of serines 303, 304, and 328 with aspartates disrupts the sh3 domain-mediated intramolecular interaction in p47(phox), thereby activating the oxidase. J. Biol. Chem. 274:1999;33644-33653.
2. 558. Eur. J. Biochem. 234:1995;208-215.
3. Segal A.W., Garcia R., Goldstone A.H., Cross A.R., Jones O.T.G. Cytochrome b-245 of neutrophils is also present in human monocytes, macrophages and eosinophils. Biochem. J. 196:1981;363-367.
4. Arbiser J.L., Petros J., Klafter R., Govindajaran B., McLaughlin E.R., Brown L.F., Cohen C., Moses M., Kilroy S., Arnold R.S., Lambeth J.D. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc. Natl. Acad. Sci. USA. 99:2002;715-720 The reactive oxygen-generating enzyme Nox1 was shown to be a potent trigger of the angiogenic switch, increasing the vascularity of tumors and inducing molecular markers of angiogenesis.
5. Cheng G., Cao Z., Xu X., van Meir E.G., Lambeth J.D. Homologs of gp91phox: cloning and tissue expression of Nox 3, Nox4, and Nox5. Gene. 269:2001;131-140.
6. Coffman R.L., Seymour B.W.P., Hudak S., Jackson J., Rennick D. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science. 245:1989;308-310.
7. Fridovich I. Superoxide dismutases. Annu. Rev. Biochem. 44:1975;147-159.
8. Babior B.M. NADPH oxidase: an update. Blood. 93:1999;1464-1476.
9. Weiss S.J., Test S.T., Eckmann C.M., Roos D., Regiani S. Brominating oxidants generated by human eosinophils. Science. 234:1986;200-202.
10. Arlandson M., Decker T., Roongta V.A., Bonilla L., Mayo K.H., MacPherson J.C., Hazen S.L., Slungaard A. Eosinophil peroxidase oxidation of thiocyanate. Characterization of major reaction products and a potential sulfhydryl-targeted cytotoxicity system. J. Biol. Chem. 276:2001;215-224.
11. Steinbeck M.J., Khan A.U., Karnovsky M.J. Intracellular singlet oxygen generation by phagocytosing neutrophils in response to particles coated with a chemical trap. J. Biol. Chem. 267:1992;13425-13433.
12. Steinbeck M.J., Khan A.U., Karnovsky M.J. Extracellular production of singlet oxygen by stimulated macrophages quantified using 9,10- diphenylanthracene and perylene in a polystyrene film. J. Biol. Chem. 268:1993;15649-15654.
13. 3.
14. Lerner R.A., Eschenmoser A. Ozone in biology. Proc. Natl. Acad. Sci. USA. 100:2003;3013-3015 An informative commentary discussing the formation and role of ozone in biological systems.
15. Wentworth P. Jr., McDunn J.E., Wentworth A.D., Takeuchi C., Nieva J., Jones T., Bautista C., Ruedi J.M., Gutierrez A., Janda K.D.et al. Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science. 298:2002;2195-2199 This study suggests that the antibody-catalyzed water-oxidation pathway produces both hydrogen peroxide and a molecular species with a chemical signature similar to that of ozone, which mediate the killing of bacteria.
16. Wink D.A., Nims R.W., Saavedra J.E., Utermahlen W.E. Jr., Ford P.C. The Fenton oxidation mechanism: reactivities of biologically relevant substrates with two oxidizing intermediates differ from those predicted for the hydroxyl radical. Proc. Natl. Acad. Sci. USA. 91:1994;6604-6608.
17. Gardner P.R., Fridovich I. Superoxide sensitivity of the Escherichia coli 6-phosphogluconate dehydratase. J. Biol. Chem. 266:1991;1478-1483.
18. Gardner P.R., Fridovich I. Superoxide sensitivity of the Escherichia coli aconitase. J. Biol. Chem. 266:1991;19328-19333.
19. Hausladen A., Fridovich I. Superoxide and peroxynitrite inactivate aconitases, but nitric oxide does not. J. Biol. Chem. 269:1994;29405-29408.
20. Schalk I., Zeng K., Wu S.-K., Stura E.A., Matteson J., Huang M., Tandon A., Wilson I.A., Balch W.E. Structure and mutational analysis of Rab GDP-dissociation inhibitor. Nature. 381:1996;42-48.
21. PHOX. J Vet Sci 2000, 1:19-26.
22. Cross A.R., Rae J., Curnutte J.T. Cytochrome b245 of the neutrophil superoxide-generating system contains two nonidentical hemes. Potentiometric studies of a mutant form of gp91phox. J. Biol. Chem. 270:1995;17075-17077.
23. 558 in the NADPH oxidase of porcine neutrophils. FEBS Lett. 377:1995;345-348.
24. Fujii H., Finnegan M.G., Johnson M.K. The active form of the ferric heme in neutrophil Cytochrome b(558) is low-spin in the reconstituted cell-free system in the presence of amphophil. J. Biochem. (Tokyo). 126:1999;708-714.
25. Smith R.M., Curnutte J.T., Mayo L.A., Babior B.M. Use of an affinity label to probe the function of the NADPH binding component of the respiratory burst oxidase of human neutrophils. J. Biol. Chem. 264:1989;12243-12248.
26. Smith R.M., Curnutte J.T., Babior B.M. Affinity labeling of the cytosolic and membrane components of respiratory burst oxidase by the 2′,3′-dialdehyde derivative of NADPH. Evidence for a cytosolic location of the nucleotide-binding site in the resting cell. J. Biol. Chem. 264:1989;1958-1962.
27. Smith R.M., Connor J.A., Chen L.M., Babior B.M. The cytosolic subunit p67phox contains an NADPH-binding site that participates in catalysis by the leukocyte NADPH oxidase. J. Clin. Invest. 98:1996;977-983.
28. PHOX, a cystosolic subunit of the leukocyte NADPH oxidase. Biochemistry. 38:1999;5746-5753.
29. Freeman J.L., Lambeth J.D. NADPH oxidase activity is independent of p47phox in vitro. J. Biol. Chem. 271:1996;22578-22582.
30. Inanami O., Johnson J.L., McAdara J.K., El Benna J., Faust L.P., Newburger P.E., Babior B.M. Activation of the leukocyte NADPH oxidase by phorbol ester requires the phosphorylation of p47phox on serine S303 or S304. J. Biol. Chem. 273:1998;9539-9543.
31. Johnson J.L., Park J.W., El Benna J., Faust L.P., Inanami O., Babior B.M. Activation of p47(PHOX), a cytosolic subunit of the leukocyte NADPH oxidase. Phosphorylation of ser-359 or ser-370 precedes phosphorylation at other sites and is required for activity. J. Biol. Chem. 273:1998;35147-35152.
32. Hoyal C.R., Gutierrez A., Young B.M., Catz S.D., Lin J.H., Tsichlis P.N., Babior B.M. Modulation of p47PHOX activity by site-specific phosphorylation: Akt-dependent activation of the NADPH oxidase. Proc. Natl. Acad. Sci. USA. 100:2003;5130-5135 Activation of the oxidase by a kinase other than protein kinase C. This work brings the oxidase into the domain of phosphoinositide 3-kinase.
33. Groemping Y., Lapouge K., Smerdon M.J., Rittinger K. Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell. 113:2003;343-355 A highly original crystallographic study that reveals a great deal about how the oxidase is activated.
34. Dinauer M.C., Pierce E.A., Bruns G.A.P., Curnutte J.T., Orkin S.H. Human neutrophil Cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J. Clin. Invest. 86:1990;1729-1737.
35. Lapouge K., Smith S.J., Groemping Y., Rittinger K. Architecture of the P40-p47-p67 phox complex in the resting state of the NADPH oxidase. A central role for p67phox. J. Biol. Chem. 277:2002;10121-10128.
36. phox. J. Exp. Med. 184:1996;893-902.
37. Sathyamoorthy M., de Mendez I., Adams A.G., Leto T.L. p40phox down-regulates NADPH oxidase activity through interactions with its SH3 domain. J. Biol. Chem. 272:1997;9141-9146.
38. Suh Y.-A., Arnold R.S., Lassegue B., Shi J., Xu X., Sorescu D., Chung A.B., Griendling K.K., Lambeth J.D. Cell transformation by the superoxide-generating oxidase Mox1. Nature. 401:1999;79-82.
39. Szocs K., Lassegue B., Sorescu D., Hilenski L.L., Valppu L., Couse T.L., Wilcox J.N., Quinn M.T., Lambeth J.D., Griendling K.K. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler. Thromb. Vasc. Biol. 22:2002;4-5 An important study concerning the relationship between the NADPH oxidases (in this case a nox) and vascular injury.
40. Sorescu D., Weiss D., Lassegue B., Clempus R.E., Szocs K., Sorescu G.P., Valppu L., Quinn M.T., Lambeth J.D., Vega J.D.et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 105:2002;1429-1435 A study tying superoxide production by NADPH oxidases to atherosclerosis.
41. PHOX. Structure at 1.8. Å resolution and biochemical characterization of the A182V mutant implicated in chronic granulomatous disease J. Biol. Chem. 276:2001;21627-21631.
42. PHOX bound to phosphatidylinositol 3-phosphate. Mol. Cell. 8:2001;829-839.
43. Casimir C., Chetty M., Bohler M.-C., Garcia R., Fischer A., Griscelli C., Johnson B., Segal A.W. Identification of the defective NADPH-oxidase component in chronic granulomatous disease: a study of 57 European families. Eur. J. Clin. Invest. 22:1992;403-406.
44. Clark R.A., Malech H.L., Gallin J.I., Nunoi H., Volpp B., Pearson D.W., Nauseef W.M., Curnutte J.T. Genetic variants of chronic granulomatous disease: prevalence of deficiencies of two discrete cytosolic components of the NADPH oxidase system. N. Engl. J. Med. 321:1989;647-652.
45. Curnutte J.T., Scott P.J., Mayo L.A. Cytosolic components of the respiratory burst oxidase: resolution of four components, two of which are missing in complementing types of chronic granulomatous disease. Proc. Natl. Acad. Sci. USA. 86:1989;825-829.
46. Curnutte J.T., Whitten D.M., Babior B.M. Defective superoxide production by granulocytes from patients with chronic granulomatous disease. N Engl. J. Med. 290:1974;593-597.
47. Forrest CB, Forehand JR, Axtell RA, Roberts RL, Johnston RB Jr: Clinical features and current management of chronic granulomatous disease. In Hematology/Oncology Clinics of North America. Phagocytic Defects II, Vol. 2. Edited by Curnutte JT. Philadelphia: W.B. Saunders; 1988:253-266.
48. Johnston R.B., Newman S.L. Chronic granulomatous disease. Pediatr. Clin. North Am. 24:1977;365-376.
49. Babior B.M., Woodman R.C. Chronic granulomatous disease. Semin Hematol. 27:1990;247-259.
50. Dinauer M.C., Orkin S.H. Chronic granulomatous disease. Annu. Rev. Med. 43:1992;117-124.
51. Speert D.P., Bond M., Woodman R.C., Curnutte J.T. Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense. J. Infect. Dis. 170:1994;1524-1531.
52. Corrado M.L., Cleri D., Fikrig S.M., Phillips J.C., Ahonkhai V.I. Aspergillosis in chronic granulomatous disease: therapeutic considerations. Am. J. Dis. Child. 134:1980;1092-1094.
53. Chang Y.C., Segal B.H., Holland S.M., Miller G.F., Kwon-Chung K.J. Virulence of catalase-deficient aspergillus nidulans in p47(phox)-/- mice. Implications for fungal pathogenicity and host defense in chronic granulomatous disease. J. Clin. Invest. 101:1998;1843-1850.
54. Fischer A., Segal A.W., Seger R., Weening R.S. The management of chronic granulomatous disease. Eur. J. Pediatr. 152:1993;896-899.
55. Ahlin A., Elinder G., Palmblad J. Dose-dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients. Blood. 89:1997;3396-3401.
56. Gallin J.I., Alling D.W., Malech H.L., Wesley R., Koziol D., Marciano B., Eisenstein E.M., Turner M.L., DeCarlo E.S., Starling J.M., Holland S.M. Itraconazole to prevent fungal infections in chronic granulomatous disease. N. Engl. J. Med. 348:2003;2416-2422 A very important addition to the therapeutic armimentarium for patients with chronic granulomatous disease.
57. Rappeport J.M., Smith B.R., Parkman R., Rosen F.S. Application of bone marrow transplantation in genetic diseases. Clin. Haematol. 12:1983;755-773.
58. Seger R.A., Gungor T., Belohradsky B.H., Blanche S., Bordigoni P., Di Bartolomeo P., Flood T., Landais P., Müller S., Ozsahin H.et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood. 100:2002;4344-4350.
59. Bolscher B.G.J.M., deBoer M., deKlein A., Weening R.S., Roos D. Point mutations in the β-subunit of Cytochrome b558 leading to X-linked chronic granulomatous disease. Blood. 77:1991;2482-2487.
60. Bu-Ghanim H.N., Segal A.W., Keep N.H., Casimir C.M. Molecular analysis in three cases of X91- variant chronic granulomatous disease. Blood. 86:1995;3575-3582.
61. Newburger P.E., Skalnik D.G., Hopkins P.J., Eklund E.A., Curnutte J.T. Mutations in the promoter region of the gene for gp91-phox in X-linked chronic granulomatous disease with decreased expression of Cytochrome b558. J. Clin. Invest. 94:1994;1205-1211.
62. Roos D., de Boer M., Kuribayashi F., Meischl C., Weening R.S., Segal A.W., Ahlin A., Nemet K., Hossle J.P., Bernatowska-Matuszkiewicz E., Middleton-Price H. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood. 87:1996;1663-1681.
63. Casimir C.M., Bu-Ghanim H.N., Rodaway A.R.F., Bentley D.L., Rowe P., Segal A.W. Autosomal recessive granulomatous disease caused by deletion at a dinucleotide repeat. Proc. Natl. Acad. Sci. USA. 88:1991;2753-2757.
64. Roesler J., Gorlach A., Rae J., Hopkins P.J., Patino P., Lee P., Curnutte J.T., Chanock S.J. Recombination events between the normal p47-phox gene and a highly homologous pseudogene are the main cause of autosomal recessive chronic granulomatous disease. Blood. 86:1995;260a.
65. Groemping Y., Lapouge K., Smerdon M.J., Rittinger K. Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell. 113:2002;343-355.